Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV130 Trained Immunity Study
NCT05208060Phase 2Recruiting
- Sponsor
- Inmunotek
- Start
- Sep 2023
- Primary completion
- Jan 2025
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MV130 in respiratory tract infection (RTI), sponsored by Inmunotek. Started Sep 2023; status: recruiting.
02
Drugs
MV130
03
Conditions
respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT05208060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208060.